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Neurological disorders (Alzheimer’s disease, vascular and mixed dementia) and visual loss
(cataract, age-related macular degeneration, glaucoma, and diabetic retinopathy) are among
the most common conditions that afflict people of at least 65 years of age. An increasing
body of evidence is emerging, which demonstrates that memory and vision impairment
are closely, significantly, and positively linked and that statins and aspirin may lessen the
risk of developing age-related visual and neurological problems. However, clinical studies
have produced contradictory results. Thus, the intent of the present study was to reliably
establish whether a relationship exist between various types of dementia and age-related
vision disorders, and to establish whether statins and aspirin may or may not have bene-
ficial effects on these two types of disorders. We found that participants with dementia
and/or vision problems were more likely to be depressed and displayed worse functional
ability in basic and instrumental activities of daily living than controls. Mini mental state
examination scores were significantly lower in patients with vision disorders compared
to subjects without vision disorders. A closer association with macular degeneration was
found in subjects with Alzheimer’s disease than in subjects without dementia or with
vascular dementia, mixed dementia, or other types of age-related vision disorders. When
we considered the associations between different types of dementia and vision disorders
and the use of statins and aspirin, we found a significant positive association between
Alzheimer’s disease and statins on their own or in combination with aspirin, indicating that
these two drugs do not appear to reduce the risk of Alzheimer’s disease or improve its
clinical evolution and may, on the contrary, favor its development. No significant association
in statin use alone, aspirin use alone, or the combination of these was found in subjects
without vision disorders but with dementia, and, similarly, none in subjects with vision
disorders but without dementia. Overall, these results confirm the general impression so
far; namely, that macular degeneration may contribute to cognitive disorders (Alzheimer’s
disease in particular). In addition, they also suggest that, while statin and aspirin use may
undoubtedly have some protective effects, they do not appear to be magic pills against the
development of cognitive impairment or vision disorders in the elderly.
Keywords: age-related vision disorders, dementia, statins, aspirin, elderly
INTRODUCTION
Dementia and vision loss among the elderly are major health
care problems. Dementia is a term used to describe a series of
conditions that can affect a person’s ability to think, remem-
ber, understand, make judgments, communicate, and interact
socially (MDGuidelines and Reed Group, 2009). Any person
can develop dementia, but it is more common after the age of
65 years (Ritchie and Lovestone, 2002). The best-known and most
common type of dementia is Alzheimer’s disease, which is char-
acterized by the presence of neurofibrillary plaques and tangles
in the brain. It can be caused by a variety of genetic, environ-
mental, and other factors. Vascular dementia is the second most
common form and occurs either due to a narrowing or a com-
plete blockage of blood vessels in the brain, which deprive brain
cells of nutrients and oxygen (Lee, 2011). Pure vascular demen-
tia is relatively uncommon; Alzheimer’s disease, exacerbated by
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cerebrovascular lesions, is more common (mixed dementia). Mild
cognitive impairment is a stage of cognitive decline between nor-
mal age-related memory loss and dementia. People with mild
cognitive impairment have memory and reasoning problems that
are evident to others, but which do not interfere with everyday life
(Petersen, 2011). Macular degeneration, cataract, and glaucoma,
as well as diabetic retinopathy, are the main causes of blindness
in the elderly, affecting approximately one person in three, by
the age of 65 years (NIH Med Plus, 2008; Pascolini and Mariotti,
2011; WHO, 2014). Over the last few years, clinical and epidemi-
ological studies have been done suggesting that dementia and
visual impairment – Alzheimer’s disease and age-related macu-
lar degeneration in particular – may share common pathogenetic
mechanisms (Blanks et al., 1996; Sarks et al., 1999; Dentchev
et al., 2003). Age-related vision impairment has been found to
be closely associated with cognitive and behavioral manifestations
(Clemons et al., 2006). Nevertheless, other studies found no sig-
nificant relationship between cognitive impairment and vision
loss in the elderly (Duron and Hano, 2008). More recently, evi-
dence has also suggested a protective effect of statins, aspirin
alone, or in combination against Alzheimer’s disease and mac-
ular degeneration (Williams et al., 2000; Jonker and Smit, 2003).
This is in line with post-mortem studies of brain tissue point-
ing to an inflammatory process associated with the extracellular
amyloid plaques characteristic of Alzheimer’s disease pathology
(Hoozemans et al., 2006), as well as with the role of inflam-
mation in macular degeneration pathogenesis. (Anderson et al.,
2002). By contrast, it has also been reported that simvastatin
(prescribed for high cholesterol) can lead to glaucoma, and that
patients who take statins are 27% more likely to develop cataracts
(Selak et al., 2014).
Aspirin is a photosensitizing drug that absorbs light energy
and undergoes a photochemical reaction resulting in chemi-
cal modification of tissue, which can increase susceptibility to
cataracts and macular degeneration (Skrzypczak-Jankun et al.,
2005). Data from a recent study of ours showed that macu-
lar degeneration patients present changes in lipid metabolism
similar to those seen in Alzheimer’s disease ones, i.e., accumu-
lation of neutral lipids in the cytoplasm of peripheral blood
mononuclear cells (Peiretti et al., 2014). We found no evidence
that statins confer protection against vision disorders or demen-
tia (Peiretti et al., 2014). In disagreement with earlier reports
(Hall et al., 2001; Baghdasarian et al., 2004), we found a defi-
nite positive association between statin use and the presence of
dementia and vision disorders (Peiretti et al., 2014). In view of
these many discrepancies, we conducted an observational study
with the aim of: firstly, quantifying the association between the
incidence and progression of age-related vision disorders and cog-
nitive impairment; secondly, evaluating the impact of statin and
aspirin use on different types of age-related vision and cognitive
disorders.
MATERIALS AND METHODS
PARTICIPANTS
In order to examine the relationship between cognitive func-
tion, dementia, and visual impairment, in this study we analyzed
data from 1,168 subjects 65 years or older admitted between 2006
and 2013 to the outpatients clinic of the geriatric care unit at
the University of Cagliari and to the one at Santissima Trinità
Hospital in Cagliari. All participants under examination under-
went dementia and/or vision problem evaluation. Subjects found
to be free from dementia or free from vision problems were utilized
as controls 1 and 2, respectively. Control 3 was a group with
neither vision problems nor dementia. Dementia and vision prob-
lems were further subdivided into categories: type of dementia:
mild cognitive impairment, Alzheimer’s disease, mixed demen-
tia, vascular dementia; type of vision problem: cataract, glau-
coma, diabetic retinopathy, macular degeneration. All participants
under examination underwent comprehensive geriatric assess-
ment; instruments used for comprehensive geriatric assessment
are described below. All participants gave informed consent. Possi-
ble/probable diagnosis of Alzheimer’s disease was made according
to the criteria of the National Institute of Neurological and Com-
municative Disorders and Stroke-Alzheimer’s Disease and Related
Disorders Association Work Group (NINCDS-ADRDA) (McK-
hann et al., 1984). Diagnosis of possible/probable vascular demen-
tia was made according to the criteria of the National Institute of
Neurological Disorders and Stroke, and of the Association Inter-
nationale pour la Recherche et l’Enseignement en Neurosciences
Work Group (NINDS-AIREN) (Roman et al., 1993). Differen-
tial diagnosis between Alzheimer’s disease, vascular dementia, and
mixed dementia was always supported by neuroimaging evidence
(computed tomography scan and/or nuclear magnetic resonance).
Subjects with symptomatic pre-dementia, but that preserved abil-
ity to function independently in daily life, were referred to as mild
cognitive impairment.
All subjects were screened at the Eye clinic, including ocular
examination by slit lamp, visual acuity tests with Snellen chart,
and intraocular pressure measurement with Goldmann applana-
tion. Fundus evaluation was done with indirect −20 diopter lens,
in order to check the posterior pole as well as the mid periph-
eral retina. More specific exams included crystalline opacification
grading after pupil dilation with tropicamide 1% by slit lamp
in order to ascertain lens opacity or type-specific opacity (Chy-
lack et al., 1993). Color fundus picture was taken in order to
classify the presence of any sign of retinal disease. Patients who
were considered as having any sign of macular degeneration in
color fundus photography – following the macular degeneration
grading system (Bird et al., 1995) – were more closely evaluated,
in a masked fashion by two observers, in order to be inves-
tigated, when necessary, with fluorescein angiography. Detailed
patient history was recorded, using a questionnaire focusing on
individual medical history. The presence of cardiovascular dis-
eases such as dyslipidemia, hypertension, and diabetes and the
use of aspirin and statins were established by reading medical
history and report analysis. To determine aspirin and statin use,
we also checked the drug boxes that each patient brought along
when undergoing the outpatient visit. Statin users were defined
as ones having used any drug in the class of 3-hydroxy-3-methyl-
glutaryl-CoA reductase inhibitors including simvastatin, fluvas-
tatin, atorvastatin, lovastatin, pravastatin, and rosuvastatin for at
least 2 years. Aspirin users were defined as ones routinely having
used cardioaspirin (100/150 mg per tablet) at least once a day for
2 years.
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COMPREHENSIVE GERIATRIC ASSESSMENT
All subjects underwent comprehensive geriatric assessment, con-
sisting of:
1. Activities of Daily Living index (Shah et al., 1989), which mea-
sures functional status by quantifying patient performance
in 10 activities of daily life. These activities can be grouped
according to self-care (feeding, grooming, bathing, dressing,
bowel and bladder care, and toilet use) and mobility (ambu-
lation, transfers, and stair-climbing). Five-point increments
are used in scoring, with a maximum score of 100, indicat-
ing that a patient is fully independent in physical functioning,
and a minimum score of zero, representing a totally dependent,
bed-ridden state.
2. Instrumental Activities of Daily Living scale (Lawton and
Brody, 1969), which assesses independence in eight activi-
ties that are more cognitively and physically demanding than
activities of daily living, including managing finances, taking
medications, using telephones, shopping, using transportation,
preparing meals, doing housework, and washing. A score of 8
indicates total autonomy, and 0, total dependence.
3. Mini Mental State Examination, which assesses cognitive sta-
tus (corrected for age and education), 30 correct-answer points
indicating cognitive deficit absence, and zero, maximum cog-
nitive deficit. Subjects with a mini mental state examination
score<24 were considered cognitively impaired (Folstein et al.,
1975; Measso et al., 1993).
4. Geriatric Depression Scale, which assesses depression symp-
toms. Of the 15 items, scores of 0–4 are considered normal; 5–8
indicate mild depression; 9–11 indicate moderate depression;
and 12–15 indicate severe depression (Yesavage et al., 1983).
5. Cumulative Illness Rating Scale (Parmelee et al., 1995), which
assesses comorbidity. The cumulative illness rating scale uses
a five-point ordinal scale (scores 1–5) to estimate the sever-
ity of pathology in each of 14 items representing individ-
ual body systems, including cardiac, vascular, respiratory,
endocrine/metabolic, gastrointestinal (upper), gastrointesti-
nal (lower), hepatic, genitourinary, musculoskeletal, ophthal-
mologic/otolaryngologic, renal, neurologic, psychiatric, and
hypertension. Each system is assigned a value ranging from
1 (no impairment) to 5 (extremely severe). A total cumulative
illness rating scale score is obtained by summing the scores for
all 14 items. The maximum impairment (MI) score represents
maximum organ damage. The comorbidity index score, which
reflects the number of concomitant diseases, is derived from the
total number of categories in which moderate or severe levels
(grades 3–5) of a chronic disease are identified (range 0–14).
The severity index reflects the overall severity of diseases, and
the average rating of 13 disease categories, excluding psychiatric
behavioral problems (range 1–5).
STATISTICAL ANALYSIS
Quantitative variables were shown as mean± SD. Comparisons
between these variables were made by Student’s t -test or vari-
ance analysis (ANOVA). If a major effect was observed, a post hoc
test (Bonferroni) was carried out to identify significant differences
between categories. An odds ratio (OD) chi-square test was also
performed to identify statistically significant associations. All sta-
tistical tests were made using Excel’s data analysis tool. A P-value
of 0.05 was considered statistically significant.
RESULTS
The population included 1,168 subjects 65 years or older, admitted
between 2006 and 2013 to the outpatients clinic of the geriatric
care unit at the University of Cagliari and to the one at Santissima
Trinità Hospital in Cagliari, of which 336 men (29%) and 832
women (71%), with a mean age of 78.4 years (±7.1) and an age
range from 65 to 100 years.
We initially analyzed comprehensive geriatric assessment data
in various types of dementia (Alzheimer’s disease, mixed demen-
tia, vascular dementia) as well as in mild cognitive impairment.
Considered together, patients with dementia (n= 551) had lower
mini mental state examination scores, activities of daily living
and instrumental activities of daily living scores, and higher geri-
atric depression scale scores than Control 1. The average age of
patients and of Control 1 was not statistically different (data
not shown). In mild cognitive impairment subjects, mini men-
tal state examination scores and instrumental activities of daily
living scores were significantly lower than those of Control 1,
but higher than Alzheimer’s disease, mixed dementia, and vas-
cular dementia patients’ (Table 1). Interestingly, Alzheimer’s dis-
ease patients differ significantly from vascular dementia patients
regarding the geriatric depression scale. Similarly, regarding the
cumulative illness rating scale and severity and comorbidity
indices, Alzheimer’s disease patients’ scores were lower than vas-
cular dementia and mixed dementia patients’, indicating that
Alzheimer’s disease patients are less depressed, have a lower comor-
bidity level, both regarding global severity and the number of
comorbidities (Table 1). As expected, subjects with any type of
age-related vision disorders (n= 438), cataract, macular degen-
eration, glaucoma, and diabetic retinopathy, were more likely to
be depressed, but, surprisingly, had significantly lower mini men-
tal state examination scores than Control 2 (data not shown).
Comparison of comprehensive geriatric assessment parameters
by ANOVA regarding the various types of vision disorders showed
significant differences in mini mental state examination, geri-
atric depression scale, instrumental activities of daily living, and
comorbidity index scores. The post hoc Bonferroni test did not
reach statistical significance for any of the estimated parameters
(Table 2). However, when a t -test was performed, mini men-
tal state examination scores were statistically significantly lower
(P = 0.008) in macular degeneration patients than Control 2, and
cataract and retinopathy patients’ geriatric depression scale scores
were significantly higher (P = 0.005 and 0.042, respectively) than
Control 2.
Considering that a large number of studies have suggested that
subjects with cardiovascular diseases have a higher risk of demen-
tia than those without cardiovascular disease, we also tested to
see whether a relationship existed between the various types of
dementia (Table 3) and dyslipidemia, general atherosclerosis, dia-
betes, and hypertension. Compared with Control 1, none of these
individual diseases were positively associated with any type of
dementia or with Alzheimer’s disease. Significant association was
found between atherosclerosis and mild cognitive impairment,
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Table 1 | Comprehensive geriatric assessment testing for subjects with different types of dementia.
1 2 3 4 5 ANOVA P -value Bonferroni at 0.05
Controls 1 (n=436) MCI (n=181) AD (n=230) MD (n=126) VD (n=195)
Age (years) 78.8±7.5 77.7±6.8 78.5±7.0 77.8±6.4 78.4±6.5 ns ns
MMSE score 27.4±1.7 24.0±2.6 17.0±5.4 17.3±4.5 18.0±4.8 0.000 1 vs. 2, 3, 4, 5
2 vs. 3, 4, 5
GDS score 8.2±3.9 8.8±3.9 8.0±4.4 8.6±4.5 9.7±3.5 0.000 1 vs. 5
3 vs. 5
ADLs score 71.2±22.9 68.5±20.9 67.2±24.6 67.2±24.2 62.9±24.1 0.001 1 vs. 5
IADL score 3.6±2.4 2.7±2.0 2.0±1.9 1.9±1.9 1.9±1.7 0.000 1 vs. 2, 3, 4, 5
2 vs. 4, 5
CIRS score 31.0±4.7 32.1±4.6 28.8±6.7 31.5±5.5 32.4±4.3 0.000 1 vs. 5
3 vs. 1, 2, 4, 5
CIRS-MI 3.6±0.5 3.6±0.5 3.6±0.5 3.7±0.5 3.7±0.5 ns ns
CIRS-SI 2.2±0.3 2.2±0.4 2.0±0.5 2.2±0.4 2.3±0.3 0.000 3 vs. 1, 2, 4, 5
CIRS-CI 6.7±2.1 7.2±2.2 5.6±2.9 6.9±2.5 7.3±2.0 0.000 1 vs. 3, 5
3 vs. 2, 4, 5
Results are shown as mean±SD.
Statistically significant differences according to ANOVA are indicated in bold type.
MCI, mild cognitive impairment; AD, Alzheimer’s disease; MD, mixed dementia; VD, vascular dementia; MMSE, mini mental state examination; GDS, geriatric depres-
sion scale; ADL, activities of daily living; IADL, instrumental activities of daily living; CIRS, cumulative illness rating scale; CIRS-MI, maximum impairment; CIRS-SI,
severity index; CIRS-CI, comorbidity index.
Table 2 | Comprehensive geriatric assessment parameters in subjects with different types of age-related vision disorders.
1 2 3 4 5 ANOVA
P -value
Bonferroni
at 0.05
Control 2 (n=730) Cataract (n=195) AMD (n=119) Glaucoma (n=51) Retinopathy (n=73)
Age (years) 78.5±6.7 78.3±8.4 78.4±6.9 77.9±8.2 78.2±6.7 ns ns
MMSE score 22.5±6.0 22.0±5.5 20.9±6.3 21.3±5.9 21.5±5.9 0.044 ns
GDS score 8.3±4.0 9.2±4.0 8.6±3.9 8.3±4.0 9.3±4.0 0.029 ns
ADLs score 68.5±24.4 65.7±21.5 68.5±21.9 68.7±23.1 70.1±22.9 ns ns
IADL score 2.8±2.3 2.2±1.9 2.4±2.0 3.0±2.1 2.4±2.0 0.004 ns
CIRS score 30.6±5.1 32.2±4.7 30.6±6.2 32.6±5.3 32.0±6.4 ns ns
CIRS-MI 3.6±0.5 3.7±0.5 3.6±0.5 3.6±0.5 3.5±0.5 ns ns
CIRS-SI 2.1±0.4 2.2±0.3 2.1±0.5 2.3±0.4 2.2±0.5 ns ns
CIRS-CI 6.5±2.3 7.0±2.3 6.5±2.9 7.6±2.2 7.2±3.1 0.000 ns
Results are shown as mean±SD.
Statistically significant differences according to ANOVA are indicated in bold type.
AMD, age-related macular degeneration; MMSE, mini mental state examination; GDS, geriatric depression scale; ADL, activities of daily living; IADL, instrumental
activities of daily living; CIRS, cumulative illness rating scale; CIRS-MI, maximum impairment; CIRS-SI, severity index; CIRS-CI, comorbidity index.
mixed dementia, and vascular dementia, and one between diabetes
and mixed dementia (Table 3).
As shown in Table 4, all types of dementia considered by us
were found, taken collectively, to be positively associated with
all types of vision disorders considered by us, taken collectively.
Furthermore, Alzheimer’s disease, mixed dementia, and vascular
dementia were found to be individually associated with all types of
vision disorders considered by us, taken collectively. In addition,
Alzheimer’s disease was found to be positively associated with mac-
ular degeneration; mixed dementia, with glaucoma and macular
degeneration; and vascular dementia,with retinopathy. It is impor-
tant to underline the association between Alzheimer’s disease and
macular degeneration.
We considered the various associations by determining chi-
square test. The associations between the dementia categories and
aspirin use alone, statin use alone, and the combination of these
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Table 3 | Relationship between cardiovascular diseases and dementia.
Participants Total
(n=1168)
Control 1
(n=436)
All types of dementia
(n=551)
MCI
(n=181)
AD
(n=230)
DM
(n=126)
DV
(n=195)
Dyslipidemia No n=241 n=195 n=96 n=123 n=66 n=109
Yes n=394 n=338 n=85 n=107 n=60 n=86
χ2 0.255 0.307 0.231 0.399 0.025
P -value 0.6137 0.5795 0.6310 0.5275 0.8743
OD (95%CI) 1.1 (0.8–1.3) 1.1 (0.8–1.5) 1.1 (0.8–1.5) 1.1 (0.8–1.7) 1.0 (0.7–1.4)
Atherosclerosis No n=208 n=228 n=64 n=121 n=47 n=76
Yes n=308 n=424 n=117 n=109 n=79 n=119
χ2 3.864 9.411 1.702 5.158 4.920
P -value 0.0493 0.0022 0.1920 0.0231 0.0265
OD (95% CI) 1.3 (1.0–1.6) 1.7 (1.2–2.4) 0.8 (0.6–1.1) 1.5 (1.0–2.3) 1.4 (1.0–2.0)
Diabetes No n=311 n=125 n=127 n=158 n=74 n=145
Yes n=504 n=228 n=54 n=72 n=52 n=50
χ2 0.875 0.100 0.590 8.690 0.731
P -value 0.3495 0.7516 0.4425 0.0032 0.3926
OD (95% CI) 1.1 (0.9–1.5) 1.1 (0.7–1.5) 1.1 (0.8–1.6) 1.7 (1.2–2.6) 0.9 (0.6–1.3)
Hypertension No n=106 n=330 n=37 n=65 n=24 n=41
Yes n=167 n=565 n=144 n=165 n=102 n=154
χ2 0.77 1.280 1.447 1.841 0.965
P -value 0.5395 0.2579 0.2291 0.1749 0.3259
OD (95% CI) 1.1 (0.8–1.4) 1.2 (0.8–1.9) 0.8 (0.6–1.2) 1.4 (0.8–2.2) 1.2 (0.8–1.8)
Significant differences are in bold type.
MCI, mild cognitive impairment; AD, Alzheimer’s disease; MD, mixed dementia; VD, vascular dementia.
last two, were found to be statistically positively significant com-
pared to aspirin non-use. Similarly, aspirin use alone was found to
be significantly associated with mild cognitive impairment, mixed
dementia, and vascular dementia in particular. Compared to statin
non-use, statin use alone was found to be significantly positively
associated with all types of dementia considered by us, taken
collectively, and also with Alzheimer’s disease. Furthermore, the
combination of aspirin and statin use was associated with all types
of dementia considered by us, taken collectively, and with mild
cognitive impairment, Alzheimer’s disease, mixed dementia and
vascular dementia in particular (Table 4).
The effects of aspirin use alone, statin use alone, and the combi-
nation of these were also assessed in patients with vision disorders
but without any type of dementia (n= 150) and in Control 3
(n= 295). The number of patients with vision disorders taking
aspirin alone, statin alone, and the combination of these was 55,
46, and 21, respectively; while the number of Control 3 taking
aspirin alone, statin alone, and the combination of these was 118,
101, and 57, respectively.
Comparing Control 3 with patients with vision disorders but
without any type of dementia, no significant association was found
for statin use alone (chi-square test 0.573, P = 0.4490, OR= 1.18,
95% CI 0.77–1.80), for aspirin use alone (chi-square test 0.465,
P = 0.4953, OR= 1.15, 95% CI 0.77–1.73), or for the combina-
tion of these (chi-square test 1.948, P = 0.1628, OR= 1.47, 95%
CI 0.85–2.54).
Commonly prescribed statins are identified by their lipophilic
or hydrophilic nature (Kobayashi et al., 2008) and have different
recommended dosages (Watson, 2008). It has been suggested that
the majority of side effects of statins are related to their lipophilic
nature and are dose-dependent. In terms of lipophilic nature,
lovastatin and simvastatin are the most lipophilic, followed by
atorvastatin, fluvastatin, and pravastatin. Rosuvastatin is a rela-
tively new statin, having a polar methane sulfonamide group, and
can be placed between fluvastatin and pravastatin. While a num-
ber of studies have investigated the effects of the hydrophilic or
lipophilic nature of statins on cognitive status in rodents (Vecka
et al., 2004; Thelen et al., 2006; Stuart et al., 2013), similar stud-
ies in humans have been few. Therefore, we also decided to assess
whether cognitive status is differently affected by their hydrophilic
or lipophilic nature and/or by the dose of statins.
Four hundred and fifty-five patients taking statins were divided
into three groups and analyzed according to their mini mental state
examination score; group 1: 144 patients, 138 of whom taking sim-
vastatin, and 6 lovastatin; group 2: 190 taking atorvastatin; group
3: 121 patients, 6 of whom taking fluvastatin, 89 rosuvastatin, and
26 pravastatin. Chi-square test was performed in order to establish
whether lipophilic nature and/or statin dose, affect cognitive sta-
tus. As shown in Table 5, no type of statin or statin dose was found
to be significantly associated with mini mental state examination
<24 score, indicating that statins may affect cognition irrespective
of their lipophilicity and dose.
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Table 4 | Associations between dementia and vision disorders.
Participants Total
(n=1168)
Control 1
(n=436)
All types of dementia
(n=732)
MCI
(n=181)
AD
(n=230)
MD
(n=126)
VD
(n=195)
All vision disorders No n=297 n=433 n=117 n=135 n=68 n=113
yes n=139 n=299 n=64 n=95 n=58 n=82
χ2 9.37 0.70 5.87 8.60 6.12
P-value 0.002 0.40 0.015 0.003 0.013
OD (95% CI) 1.5 (1.1–1.9) 1.2 (0.8–1.7) 1.5 (1.1–2.1) 1.8 (1.2–2.7) 1.5 (1.1–2.2)
Cataract No n=297 n=433 n=117 n=135 n=68 n=113
yes n=72 n=123 n=30 n=32 n=23 n=38
χ2 0.90 0.053 0.009 1.838 2.053
P-value 0.340 0.817 0.924 0.175 0.151
OD (95% CI) 1.2 (0.8–1.6) 1.1 (0.7–1.7) 1.0 (0.6–1.5) 0.7 (0.4–12.2) 1.4 (0.9–2.2)
Glaucoma No n=297 n=433 n=117 n=135 n=68 n=113
yes n=17 n=34 n=7 n=5 n=15 n=7
χ2 1.03 0.007 0.73 14.05 0.024
P-value 0.381 0.935 0.391 0.0002 0.875
OD (95% CI) 1.4 (0.7–25) 1.0 (0.4–2.6) 1.6 (0.2–1.8) 3.8 (1.8–8.0) 1.1 (0.4–2.7)
Retinopathy No n=297 n=433 n=117 n=135 n=68 n=113
yes n=19 n=54 n=15 n=16 n=6 n=17
χ2 5.97 3.801 3.09 0.44 6.19
P-value 0.014 0.051 0.078 0.507 0.013
OD (95% CI) 2.0 (1.1–3.4) 2.1 (1.0–4.1) 1.8 (0.9–3.7) 1.4 (0.5–3.6) 2.3 (1.2–4.7)
AMD No n=297 n=433 n=117 n=135 n=68 n=113
yes n=31 n=88 n=12 n=42 n=14 n=20
χ2 9.24 0.002 18.95 3.90 3
P-value 0.002 0.960 0.000 0.048 0.083
OD (95% CI) 1.9 (1.3–3.0) 1.0 (0.5–2.0) 3.0 (1.8–4.9) 2.0 (1.0–3.9) 1.7 (0.9–3.1)
Statin users No n=288 n=401 n=92 n=124 n=72 n=113
Yes n=148 n=331 n=89 n=106 n=54 n=82
χ2 14.35 12.53 9.40 9.40 3.82
P-value 0.0002 0.0004 0.002 0.066 0.050
OD (95% CI) 1.6 (1.3–2.0) 1.9 (1.3–2.7) 1.7 (1.2–2.3) 1.5 (1.0–2.2) 1.4 (1.0–2.0)
Aspirin users No n=259 n=352 n=85 n=130 n=47 n=90
Yes n=177 n=380 n=96 n=100 n=79 n=105
χ2 14.02 8.02 0.51 19.25 9.57
P-value 0.0002 0.005 0.473 0.000 0.002
OD (95% CI) 1.6 (1.2–2.0) 1.6 (1.2–2.3) 1.1 (0.8–1.6) 2.5 (1.6–3.7) 1.7 (1.2–2.4)
Statin+Aspirin users No n=192 n=214 n=35 n=79 n=37 n=63
yes n=81 n=193 n=40 n=55 n=43 n=55
χ2 21.39 14.52 5.22 15.74 10.42
P-value 0.000 0.0001 0.022 0.001 0.0012
OD (95% CI) 2.1 (1.5–3.0) 2.7 (1.6–4.6) 1.6 (1.1–2.5) 2.7 (1.6–4.6) 2.1 (1.3–3.2)
Significant differences are in bold types.
AMD, age-related macular degeneration; MCI, mild cognitive impairment; AD, Alzheimer’s disease; MD, mixed dementia; VD, vascular dementia.
However, when different types of dementia were considered,
chi-square test was found to be significant (P = 0.036). In particu-
lar, we found that the most lipophilic statins (group 1) were taken
by 33% of Alzheimer’s disease patients, 13% of mixed dementia
ones, 17% of vascular dementia ones, and 37% of mild cognitive
impairment ones, while the most hydrophilic statins (group 3),
by 22% of Alzheimer’s disease patients, 13% of mixed dementia
ones, 38% of vascular dementia ones, and 27% of mild cognitive
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Table 5 | Associations between MMSE and lipophilic nature and statin
dose.
Group MMSE<24 MMSE≥24.5 Total χ2 (P -value)
1 94 50 144 3.666 (0.160)
2 113 77 190
3 65 56 121
Total 272 183 455
Dose MMSE<24 MMSE≥24 Total χ2 (P -value)
High (40–80 mg) 32 26 58 5.845 (0.054)
Low (10–20 mg) 240 157 397
Total 272 183 455
MMSE, mini mental state examination
impairment ones, indicating that lipophilic statins more frequently
give rise to the complex spectrum of non-vascular dementia, which
includes mild cognitive impairment and Alzheimer’s disease, while
hydrophilic statins give rise to vascular dementia.
DISCUSSION
Growing evidence suggests that memory impairment and age-
related vision problems are closely linked in patients with demen-
tia, therefore, vision tests have been proposed for early dementia
detection (Reischies and Geiselmann, 1997). In particular, it was
found that older patients with advanced macular degeneration
and reduced vision may be more likely to also have cognitive
impairment or problems with reasoning, learning, and memory
(Clemons et al., 2006). Several possible explanations for these asso-
ciations have been given: 1. macular degeneration and dementia
are both chronic neurodegenerative disorders affecting an increas-
ing number of people as they age. 2. A common characteristic of
macular degeneration and cognitive impairment is nerve cell loss.
3. Retina degeneration may lead to problems with both vision
and cognition. 4. It has also been hypothesized that the relation-
ship between visual and cognitive impairment may be based on
the influence of visual impairment on the level and quality of
interactive experiences of older adults, suggesting that a reduced
capacity to develop and maintain relationships and to participate
in activities may also influence physical, mental, and psychosocial
behavior (Clemons et al., 2006). In the present study, none of the
cardiovascular diseases examined were associated with any type
of dementia or with Alzheimer’s disease. Significant association
was found between atherosclerosis and mixed dementia and vas-
cular dementia, and also between diabetes and mixed dementia,
indicating that cardiovascular diseases do not appear to be risk
factors specific for dementia. By way of confirmation, a recent
study pooling raw data from 10 UK general population-based
prospective cohort studies – in the context of individual partic-
ipant meta-analysis – concludes that there is only limited evidence
that cardiovascular disease risk factors are related to death due to
dementia (Batty et al., 2014).
No significant differences in mean age were observed between
control groups and dementia or vision disorder groups. Mini men-
tal state examination scores, activities of daily living ones, and
instrumental activities of daily living ones indicate that patients
with dementia are more depressed, have higher functional dis-
ability in basic and instrumental activities of daily living than
controls. As expected, patients with poor visual acuity were more
likely to be depressed and have more comorbidity than controls,
both in terms of cumulative illness rating scale and severity index
or comorbidity index, but, surprisingly, they have significantly
lower mini mental state examination scores. When different types
of vision disorder and dementia were analyzed, we found that
patients diagnosed with Alzheimer’s disease had closer associa-
tion with macular degeneration than patients with other forms
of dementia. This study is novel in its investigation of the rela-
tionships between mild cognitive impairment, various forms of
age-related dementia (Alzheimer’s disease, mixed dementia, and
vascular dementia) and the four major recognized age-related
vision disorders, namely: cataract, macular degeneration, glau-
coma, and diabetic retinopathy. A number of studies that have
evaluated the relationship between macular degeneration and cog-
nitive impairment or dementia confirm our results. In fact, most of
these studies found an association between cognitive impairment
and late macular degeneration (Pham et al., 2006). Association
with early macular degeneration and cognitive impairment was
found only in an older population, suggesting that a pathophys-
iology is likely shared by macular degeneration and age-related
brain diseases (Baker et al., 2009). The results of a previous study
of ours were in apparent contrast: no cognitive impairment was
found – as assessed by mini mental state examination – in a group
of 136 macular degeneration patients admitted to the outpatient
eye clinic of the University of Cagliari (Peiretti et al., 2014). How-
ever, these patients were younger and macular degeneration was
not in an advanced stage. Although the results of the present study
seem to support the idea that the presence of macular degeneration
may be important for predicting Alzheimer’s disease, it remains to
be determined whether, in the case of their concurrent presence,
macular degeneration always precedes cognitive function deterio-
ration. In this study, the chi-square test confirmed that dementia is
significantly associated with vision disorders, and that Alzheimer’s
disease is closely related to macular degeneration in particular.
Another purpose of this study was to explore the impact of
statin and aspirin use on cognition and vision. Several studies
examining the relationship between dementia and statin use sug-
gest that taking statins lowers the risk of dementia (Jick et al.,
2000). However, a recent systematic review of the literature on
statins and dementia – including Alzheimer’s disease – showed
that the use of statins to prevent vascular disease did not appear
to prevent Alzheimer’s disease (McGuinness et al., 2009). Studies
have also examined the effect of non-steroidal anti-inflammatory
drugs on the development of dementia (Rist et al., 2012; Liew et al.,
2013). These studies have shown that aspirin use can actually put
people at increased risk of certain types of dementia (Rist et al.,
2012; Liew et al., 2013). However, other studies have shown no
difference in dementia risk between people who take aspirin and
those who do not (Kern et al., 2012). People who were regular
aspirin (Klein et al., 2012) and/or statin (Hall et al., 2001) users
were also reported to be affected by vision disorders – macular
degeneration in particular. In this case, too, however, conflicting
results were reported.
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In this study, we found that, compared to aspirin non-users,
aspirin users alone were significantly positively associated with
all types of dementia, taken collectively, and with mild cognitive
impairment, mixed dementia, and vascular dementia in particular.
Compared to statin non-users, statin users alone were significantly
positively associated with all types of dementia, taken collec-
tively and with Alzheimer’s disease. The combination of these two
drugs was associated with all types of dementia, taken collectively,
and with mild cognitive impairment, Alzheimer’s disease, mixed
dementia, and vascular dementia in particular. The association
between mild cognitive impairment, mixed dementia and vascu-
lar dementia and aspirin and statin use is not a surprise, since
mild cognitive impairment, mixed dementia, and vascular demen-
tia patients often suffer from atherosclerosis, for the treatment of
which these two drugs are prescribed. On the contrary, the positive
association between Alzheimer’s disease and statin use is less easy
to explain, since Alzheimer’s disease patients do not seem to be
associated with other age-related disorders for which statins and
aspirin are prescribed.
Comparison between Control 3 and subjects with vision disor-
ders, but without dementia, did not show significant association
for statin use alone, aspirin use alone, or the combination of these
two drugs, indicating that statins and aspirin do not appear to
protect against age-related vision disorders.
In summary, this data, not only indicate a positive effect of
statins and aspirin in lowering the risk of developing macular
degeneration or Alzheimer’s disease but even seem to suggest that
statins may favor Alzheimer’s disease development. In addition,
it offers no evidence that statins and aspirin may be used for the
improvement of vision disorders, macular degeneration in par-
ticular. The mechanism by which statins might worsen cognitive
functions is unknown, but one of the prevailing hypotheses focuses
on the role of cholesterol in the brain. Since cholesterol plays a
fundamental role in the myelination of neurons, it has been pro-
posed that excessive inhibition of cholesterol synthesis could lead
to adverse cognitive effects (Fassbender et al., 2002). Indeed, there
is some evidence that statin treatment inhibits local synthesis of
cholesterol in the central nervous system (Lütjohann et al., 2004).
In addition, if the effects of statins on memory and dementia
are mediated directly by the central nervous system, one would
predict lipophilicity to be correlated with neural effects associ-
ated with statins. Accordingly, some studies have reported that the
most lipophilic statins may have a greater propensity for cross-
ing the blood–brain barrier and affecting central nervous system
activity (Serajuddin et al., 1991). Until now, only a limited number
of studies have investigated cognitive problems in humans under-
going different types of statin therapy. In the present study, the
analysis of the effects of statin lipophilicity on learning and mem-
ory, as determined by mini mental state examination, revealed
that statins affect cognition irrespective of their lipophilicity and
dose. However, when different types of dementia were analyzed,
we found that lypophylic statins were more closely associated to
Alzheimer’s disease and mild cognitive impairment than they were
to vascular dementia.
Our results neither definitely indicate whether the regu-
lar administration of statins may induce memory changes nor
whether some statins, based on their hydrophobic/lipophilic
status,may be more beneficial than others: therefore,given the high
number of studies showing memory loss in the population receiv-
ing statins, additional studies on statins and cognition, comparing
the short- and long-term effects of various statins, are necessary.
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